Parethoxycaine

Parethoxycaine

SCHEMBL25944

CCOc1ccc(C(=O)OCCN(CC)CC)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 4/20 1.00
SCN2A Q99250 4/20 1.00
SCN3A Q9NY46 4/20 1.00
LMNA P02545 2/20 1.00
ALDH1A1 P00352 3/20 0.74
MAPT P10636 1/20 0.74
CYP2D6 P10635 4/20 0.68
HRH3 Q9Y5N1 3/20 0.68
TSHR P16473 3/20 0.68
MAOA P21397 2/20 0.68
HTR3A P46098 1/20 0.68
BLM P54132 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
ATM Q13315 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP1A2 P05177 3/20 0.57
KCNH2 Q12809 2/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A3 Q01959 1/20 0.57
HIF1A Q16665 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Parethoxycaine SCHEMBL3773020 0.98 SCN1A (0.97) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL25553 0.90 SCN1A (0.81) SCN1ASCN2ASCN3ALMNAALDH1A1
Hydrochloric Acid SCHEMBL7551157 0.88 LMNA (0.79) SCN1ASCN2ASCN3ALMNAALDH1A1
Hydrochloric Acid SCHEMBL29365036 0.88 SCN1A (0.79) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL5410731 0.88 LMNA (0.78) SCN1ASCN2ASCN3ALMNAALDH1A1
Hydrochloric Acid SCHEMBL11672435 0.87 LMNA (0.76) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL29405853 0.86 ALDH1A1 (0.97) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL10965078 0.86 SCN1A (0.75) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL11064827 0.85 ALDH1A1 (0.73) SCN1ASCN2ASCN3ALMNAALDH1A1
SCHEMBL14950264 0.84 ALDH1A1 (0.72) SCN1ASCN2ASCN3ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1977 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT UNIV KOREA RES & BUS FOUND (KR) 2026-04-30 US claimed
EP-4436552-B1 GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC OREXA B V (NL) 2026-02-04 EP claimed
WO-2025235864-A1 COATED NEEDLE ADMINISTRATION SYSTEMS EVOLUS, INC. (US) 2025-11-13 WO claimed
US-12419619-B2 Aspiration device YALE UNIVERSITY (US) 2025-09-23 US claimed
EP-4578441-A1 TREATMENT OF LOCALIZED PAIN PlantTec Medical GmbH (DE) 2025-07-02 EP claimed
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics BIOPOLIMERI S.R.L. (IT) 2025-06-17 US claimed
US-20250186364-A1 COMBINATION OF ANTISPASMODIC AND ANESTHETIC AGENTS FOR TOPICAL PRODUCTS AND THEIR METHOD OF USE PRIMA INNOVATIONS, LLC 2025-06-12 US claimed
EP-4362994-B1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S R L (IT) 2025-03-12 EP claimed
WO-2025043048-A1 METHODS AND SYSTEMS FOR DELIVERY OF MODIFIED AGAROSE POLYSACCHARIDES RELIVE THERAPEUTICS INC. (US) 2025-02-27 WO claimed
US-20250009689-A1 GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC OREXA B.V. (NL) 2025-01-09 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-1027015-A1 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE Galin, Miles A. (US) 2000-08-16 EP claimed
CN-1251979-A Controlled release of drugs in the anterior chamber of the eye MILES A GALIN (US) 2000-05-03 CN claimed
US-5972326-A Controlled release of pharmaceuticals in the anterior chamber of the eye IOLTECH (FR) 1999-10-26 US claimed
US-5939425-A ANALGESICS ADMINISTERED BY INHALATION ALGOS PHARMACEUTICAL CORPORATION (US) 1999-08-17 US claimed
EP-0932416-A2 METHOD AND POTENTIATED COMPOSITION FOR TREATING MIGRAINE Algos Pharmaceutical Corporation (US) 1999-08-04 EP claimed
WO-1998041171-A1 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE GALIN MILES A (US) 1998-09-24 WO claimed
WO-1998015275-A2 METHOD AND POTENTIATED COMPOSITION FOR TREATING MIGRAINE ALGOS PHARMACEUTICAL CORPORATION (US) 1998-04-16 WO claimed
US-4041174-A INJECTING AN ESTER LOCAL ANESTHETIC ROM-AMER PHARMACEUTICALS, LTD. (US) 1977-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics CD44, HCAR3, HCAR2 SCN1A 2618/4885SCN2A 2486/4885SCN3A 2849/4885
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT CES2, DAGLA, ACHE SCN1A 1562/4885SCN2A 501/4885SCN3A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.